Emerald Advisers’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Emerald Advisers’s Portfolio TLOG Stock Details TLOG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-163,540	Closed	-$662K	–	396
2015 Q1	$662K	Hold	163,540	–	–	0.03%	268
2014 Q4	$788K	Sell	163,540 -11,460	-7%	-$51.3K	0.04%	256
2014 Q3	$728K	Hold	175,000	–	–	0.04%	262
2014 Q2	$1.03M	Hold	175,000	–	–	0.06%	251
2014 Q1	$1.12M	Hold	175,000	–	–	0.06%	246
2013 Q4	$1.67M	Buy	+175,000	New	+$1.37M	0.09%	213

Other funds holding TLOG

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

FWC

First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CCA

Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Emerald Advisers's TLOG Position: Q2 2015 in Review

Emerald Advisers sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q2 2015, closing a stake of 163,540 shares — an estimated $662K sold.

Emerald Advisers first reported a position in TLOG in Q4 2013 and held it in 6 quarters. The position peaked at $1.67M in Q4 2013. 33 funds tracked by Wall St. Rank hold TLOG as of Q2 2015.

Emerald Advisers reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q2 2015 after selling out during the quarter.
Emerald Advisers sold 163,540 TetraLogic Pharmaceuticals Corporation shares in Q2 2015, an estimated $662K.
Emerald Advisers first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2013 and held it in 6 quarters.
Emerald Advisers's TetraLogic Pharmaceuticals Corporation position peaked at $1.67M in Q4 2013.
33 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q2 2015.

Based on Emerald Advisers's 13F filing for Q2 2015, filed 28 Jul 2015.